MagnetisMM-5

Phase 3 Clinical Trial Evaluating The Safety and Effectiveness of Elranatamab Alone and Combined with Daratumumab Compared to the Combination of Daratumumab, Pomalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Arms / Cohorts

Part 2, Arm A:Experimental Arm A: Elranatamab

Accepting patients

Part 2, Arm B:Experimental Arm B: Elranatamab and Daratumumab

Accepting patients

Part 2, Arm C:Arm C: Daratumumab, Pomalidomide and Dexamethasone

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.